PTH-121 Primary care calprotectin testing for suspected IBD: Does it reduce time to diagnosis or treatment?

IntroductionPrimary care faecal calprotectin (FC) was introduced locally in 2014 to help distinguish IBD from IBS with the additional aim of reducing time to IBD diagnosis and treatment. This study examines impact of FC on referral routes, time to diagnosis and treatment.MethodsAll patients classifi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gut 2019-06, Vol.68 (Suppl 2), p.A94
Hauptverfasser: Hicks, Amy, Selinger, Christian
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:IntroductionPrimary care faecal calprotectin (FC) was introduced locally in 2014 to help distinguish IBD from IBS with the additional aim of reducing time to IBD diagnosis and treatment. This study examines impact of FC on referral routes, time to diagnosis and treatment.MethodsAll patients classified as new referrals to IBD clinics were studied for 2013 and 2016. Of these 762 patients only 248 with a new diagnosis of IBD (248 total) were included. Data on referral routes and dates, faecal calprotectin measurements, and date of first treatment and proxy outcomes for disease severity during the 1st year (steroid use, biologic use, surgery) all at 1 year were collected. Time to diagnosis and treatment was compared using unpaired t-tests. Disease severity was analysed using chi-squared test.ResultsThere were no significant differences in baseline data between cohorts (mean age 43 years, 50% male, 17% smokers status, 35% CD, 60% UC, 5% IBD-U) and no significant difference in disease severity. The number of patients referred directly to gastroenterology rose from 3% (2013) to 17% (2016), while 10% of diagnoses were made during emergency admissions (unchanged, table 1). Referrals via the 2-week wait pathway remained high (38% 2013, 28% in 2016), whilst many had initial investigations at independent centres contracted to provide NHS care (16% in 2013, 24% in 2016).Abstract PTH-121 Table 1Routes of initial referral 2013 cohort (n=104) 2016 cohort (n=144) Initial referral Time to diagnosis (mean months) Time to treatment (mean months) Initial referral Time to diagnosis (mean months) Time to treatment (mean months) Independent NHS providers 17 N/A 1.0 34 N/A 0.8 GP to Gastro 3 2.0 0.67 25 1.16 0.44 GP to Surgeons 18 2.0 1.0 14 3.8 1.62 Colorectal 2 week wait pathway 39 0.64 1.62 40 0.6 0.89 Hospital Admission 13 0.31 0.8 14 0.07 0.31 Hepatology 3 N/A 1.33 2 3.0 0 Private care 1 0 0 7 1.14 0.8 Bowel Cancer screening 3 N/A 5.0 5 N/A 1.67 Others 7 N/A 1.6 2 N/A 0.5 Time from referral to diagnosis of IBD increased non-significantly from 2013 (0.79 months) to 2016 (1.27, p=0.2). 48 patients had FC checked prior to referral and 37.5% of these were referred direct to gastroenterology. Time to diagnosis was marginally longer in patients with FC compared to those without (1.47 vs 0.86 months, p=0.06). Time from diagnosis to treatment reduced from 1.37 (2013) to 0.72 months (2016, p=0.01).ConclusionFC has contributed to an increased proportion of referrals direct to gastroent
ISSN:0017-5749
1468-3288
DOI:10.1136/gutjnl-2019-BSGAbstracts.180